BioPharma Resources

Drugs by condition

Drugs approved for type 2 diabetes

Brand-name prescription drugs and biologics whose FDA label lists type 2 diabetes as an approved use. Matched on the label phrases: "type 2 diabetes".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

54

Still marketed, NDA or BLA

Drug classes

12

Novel drugs

22

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for type 2 diabetes.

  • Onswik (Insulin Efsitora Alfa-Gobe) · Eli Lilly and CO NovelSep 23, 2026
  • Arbli (Losartan Potassium) · Scienture Mar 13, 2025
  • Zituvimet Xr (Metformin Hydrochloride, Sitagliptin) · Zydus Lifesciences Jul 18, 2024
  • Zituvimet (Metformin Hydrochloride, Sitagliptin) · Zydus Lifesciences Nov 3, 2023
  • Zituvio (Sitagliptin) · Zydus Lifesciences Oct 18, 2023

All approved drugs for type 2 diabetes, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 266 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Sodium-Glucose Cotransporter 2 Inhibitor (7)

  • Inpefa Sotagliflozin · Lexicon Pharms INC · 2023
  • Brenzavvy Bexagliflozin · Theracosbio · 2023
  • Jardiance Empagliflozin · Boehringer Ingelheim · 2014
  • Trijardy Xr Empagliflozin, Linagliptin, Metformin Hydrochloride · Boehringer Ingelheim · 2020
  • Synjardy Xr Empagliflozin, Metformin Hydrochloride · Boehringer Ingelheim · 2016
  • Synjardy Empagliflozin, Metformin Hydrochloride · Boehringer Ingelheim · 2015
  • Glyxambi Empagliflozin, Linagliptin · Boehringer Ingelheim · 2015

Dipeptidyl Peptidase 4 Inhibitor (6)

  • Tradjenta Linagliptin · Boehringer Ingelheim · 2011
  • Zituvimet Xr Metformin Hydrochloride, Sitagliptin · Zydus Lifesciences · 2024
  • Zituvimet Metformin Hydrochloride, Sitagliptin · Zydus Lifesciences · 2023
  • Zituvio Sitagliptin · Zydus Lifesciences · 2023
  • Jentadueto Xr Linagliptin, Metformin Hydrochloride · Boehringer Ingelheim · 2016
  • Jentadueto Linagliptin, Metformin Hydrochloride · Boehringer Ingelheim · 2012

GLP-1 Receptor Agonist (4)

  • Saxenda Liraglutide · Novo · 2014
  • Trulicity Dulaglutide · Eli Lilly and CO · 2014
  • Victoza Liraglutide · Novo Nordisk INC · 2010
  • Ozempic Semaglutide · Novo · 2019

Insulin Analog (3)

Sulfonylurea (3)

  • Duetact Glimepiride, Pioglitazone Hydrochloride · Takeda Pharms USA · 2006
  • Glucotrol Xl Glipizide · Pfizer · 1994
  • Diabeta Glyburide · Sanofi Aventis US · 1984

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (1)

  • Mounjaro Tirzepatide · Eli Lilly and CO · 2022

Nonsteroidal Mineralocorticoid-Receptor Antagonist (1)

  • Kerendia Finerenone · Bayer Hlthcare · 2021

P2Y12 Platelet Inhibitor (1)

  • Brilinta Ticagrelor · Astrazeneca · 2011

Angiotensin 2 Receptor Blocker (1)

  • Avapro Irbesartan · Sanofi Aventis US · 1997

Progestin Antagonist (1)

  • Korlym Mifepristone · Corcept Therap · 2012

Peroxisome Proliferator Receptor alpha Agonist (1)

Class not listed in FDA's data (25)

  • Onswik Insulin Efsitora Alfa-Gobe · Eli Lilly and CO · 2026
  • Steglatro Ertugliflozin · Msd Sub Merck · 2017
  • Ozempic Semaglutide · Novo · 2017
  • Farxiga Dapagliflozin · Astrazeneca Ab · 2014
  • Invokana Canagliflozin · Janssen Pharms · 2013
  • Nesina Alogliptin Benzoate · Takeda Pharms USA · 2013
  • Januvia Sitagliptin Phosphate · Msd · 2006
  • Welchol Colesevelam Hydrochloride · Cosette · 2000
  • Actos Pioglitazone Hydrochloride · Takeda Pharms USA · 1999
  • Lipitor Atorvastatin Calcium · Upjohn · 1996
  • Cozaar Losartan Potassium · Organon · 1995
  • Arbli Losartan Potassium · Scienture · 2025
  • Atorvaliq Atorvastatin Calcium · Cmp Dev LLC · 2023
  • Steglujan Ertugliflozin, Sitagliptin Phosphate · Msd Sub Merck · 2017
  • Segluromet Ertugliflozin, Metformin Hydrochloride · Msd Sub Merck · 2017
  • Invokamet Xr Canagliflozin, Metformin Hydrochloride · Janssen Pharms · 2016
  • Xigduo Xr Dapagliflozin, Metformin Hydrochloride · Astrazeneca Ab · 2014
  • Invokamet Canagliflozin, Metformin Hydrochloride · Janssen Pharms · 2014
  • Kazano Alogliptin Benzoate, Metformin Hydrochloride · Takeda Pharms USA · 2013
  • Oseni Alogliptin Benzoate, Pioglitazone Hydrochloride · Takeda Pharms USA · 2013
  • Janumet Xr Metformin Hydrochloride, Sitagliptin Phosphate · Msd Sub Merck · 2012
  • Cycloset Bromocriptine Mesylate · Veroscience · 2009
  • Janumet Metformin Hydrochloride, Sitagliptin Phosphate · Msd Sub Merck · 2007
  • Actoplus Met Metformin Hydrochloride, Pioglitazone Hydrochloride · Takeda Pharms USA · 2005
  • Caduet Amlodipine Besylate, Atorvastatin Calcium · Pharmacia · 2004

Drugs in development for type 2 diabetes

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • NNC0487-0111Phase 312 trials

    Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • BofanglutideGZR18, BofanglutidaPhase 311 trials

    Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • LenbelintideAZD6234Phase 39 trials

    AstraZeneca · Obesity or Overweight, Obesity, Overweight

  • ZenagamtidePhase 39 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • OlatorepatideHS-20094Phase 38 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes

  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

  • AleniglipronPhase 36 trials

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management

  • CagriSemaCagrilintide B and Semaglutide IPhase 36 trials

    Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension

  • MWN109 1Phase 36 trials

    Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)

  • MWN109 2Phase 36 trials

    Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)

  • ASC30 A1ASC30Phase 35 trials

    Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight

  • BGM0504Phase 35 trials

    BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity

  • HDM1005Phase 35 trials

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Obstructive Sleep Apnea (OSA) and Obesity, Obesity, Type 2 Diabetes

  • MazdutideLY3305677Phase 35 trials

    Eli Lilly · Type 2 Diabetes, Obesity, Overweight

5 discontinued brand-name drugs whose label still names it

More on type 2 diabetes: recruiting trials · published research

Related in cardiovascular and metabolic: Type 1 diabetes · Obesity and weight management · High blood pressure (hypertension) · Heart failure · High cholesterol · High triglycerides · Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Stroke prevention · Coronary artery disease and heart attack

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.